Ethris, a Munich, Germany-based clinical-stage biotechnology company, received a €10M grant from EU4Health.
The company intends to allocate the amount of support NoVir, a comprehensive project including several preclinical and clinical studies to evaluate the potential of ETH47, its mRNA-based antiviral therapy.
Led by CEO Dr. Carsten Rudolph, Ethris a clinical-stage biotechnology company providing a proprietary RNA and lipidoid nanoparticle technology platform to discover, design and develop innovative therapies.
The NoVir study will run from May 1, 2025, to April 31, 2027 and will include the following projects:
- A clinical rhinovirus challenge study in asthmatic and chronic obstructive pulmonary disease (COPD) patients, populations at high risk for severe viral infections.
- A clinical study in healthy volunteers infected with influenza to assess ETH47’s antiviral efficacy.
- Preclinical research exploring ETH47’s protective effects against paramyxoviruses, orthomyxoviruses, coronaviridae, and bunyaviruses, including those responsible for viral hemorrhagic fevers (VHFs).
- Investigation into ETH47’s impact on intravaginal, ocular, and systemic infections, through multiple routes of administration, expanding its potential use beyond respiratory illnesses.
- Evaluation of ETH47’s ability to enhance the efficacy of existing antiviral treatments through synergistic effects.
FinSMEs
09/05/2025